Home › Research › Semax
RESEARCH USE ONLY — This article describes a compound studied in laboratory and pre-clinical research. It is not intended for human or animal administration.

Semax

Cognitive / Nootropic Half-life: ~30 minutes Status: Research Compound

Semax

Overview

Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro), with a Pro-Gly-Pro tripeptide extension at the C-terminus for metabolic stability. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, it is approved in Russia as a nootropic and neuroprotective medication. Its primary research distinction is potent upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), making it one of the most studied peptide-based neurotrophic modulators.

BLUF — At a Glance

A synthetic heptapeptide derived from the ACTH(4-10) fragment, studied for nootropic-related activity.

Primary research focus

  • BDNF/NGF upregulation
  • Cognitive function — attention, learning, memory
  • Neuroprotection research (pre-clinical models)

Notes: Status: research compound — not FDA-approved. Half-life ~30 min. Human trial data limited; independent Western replication limited. For research purposes only.

Mechanism of Action

Semax acts through multiple neurobiological pathways. The most consistently reported mechanism is upregulation of BDNF and NGF expression in brain regions including the hippocampus, cortex, and basal forebrain. It modulates melanocortin receptor signaling (MC3R and MC4R) derived from its ACTH fragment origin, though it lacks the adrenal steroidogenic activity of full-length ACTH. Published research also documents effects on cholinergic, dopaminergic, and serotonergic neurotransmission, as well as modulation of neuroinflammation through effects on brain mast cells and microglial activity.

Research-Indicated Benefits

  • Published research suggests significant upregulation of BDNF and NGF in multiple brain regions in animal models
  • Published research suggests improvements in attention, learning, and memory consolidation in behavioral paradigms
  • Published research suggests neuroprotective effects in cerebral ischemia and stroke animal models
  • Published research suggests modulation of dopaminergic and serotonergic neurotransmission with potential mood-related effects
  • Published research suggests anti-inflammatory effects on neuroinflammation through mast cell and microglial modulation

Typical Research Protocols

Commonly reported in research literature: 200-600 mcg administered intranasally, typically 2-3 times daily. Intranasal delivery provides direct CNS access via the olfactory pathway, bypassing the blood-brain barrier. Oral bioavailability is poor based on published pharmacokinetic data, making intranasal administration the established route. Published treatment durations in Russian clinical protocols typically range from 10 days to 4 weeks.

Safety Profile

Published Russian clinical data reports a favorable safety profile with no significant adverse effects at established doses. No hormonal effects (cortisol, ACTH stimulation) have been reported despite its ACTH fragment origin, confirming the selectivity of the truncated sequence. No dependence, tolerance, or withdrawal effects have been documented. Reported side effects in clinical use are rare and mild, occasionally including nasal irritation with intranasal administration. Independent Western replication of safety data remains limited.

Key Studies

  • Ashmarin IP, et al. Foundational research on Semax at the Russian Academy of Sciences published in Russian pharmacology journals.
  • Glazova NY, et al. "Semax, an ACTH(4-10) analogue with nootropic properties, activates BDNF and trkB gene expression in the rat hippocampus." Doklady Biological Sciences, 2005.
  • Dolotov OV, et al. Multiple studies investigating Semax effects on neurotrophic factors published in neuroscience journals.
  • Medvedeva EV, et al. Studies on Semax neuroprotective effects in ischemia models.
  • Multiple studies in Russian neuropharmacology journals have investigated Semax in cognitive and neuroprotective applications.

Interactions and Stacking

Selank is the most commonly paired compound, offering complementary anxiolytic and GABAergic mechanisms to Semax's BDNF-focused nootropic profile. This pairing represents the most discussed nootropic peptide stack in the published literature. DSIP provides complementary neuroendocrine and sleep-modulation pathways that may support cognitive recovery and stress management. BPC-157 has been studied for neuroprotective properties through different mechanisms (dopaminergic system, GI-brain axis).

For research and educational purposes only. Not medical advice.

Frequently Asked Questions

Is Semax FDA-approved?

No. Semax is not approved by the U.S. Food and Drug Administration for any clinical application. It remains classified as a research compound supplied for laboratory work only.

What does the research literature show about Semax?

The published research record for Semax is summarized in the body of this article and the citations section. Pre-clinical and animal-model studies make up the bulk of the literature; human trial data is limited and is noted explicitly where it exists.

What are the documented synergistic compounds for Semax research?

See the Related Research sidebar for compounds that appear alongside Semax in the published literature. Detailed synergy notes will populate during the next vault expansion pass.

Where can I source Semax for research purposes?

See the Where to Source section above for vendors that supply research-grade Semax. Listed vendors are affiliate partners of Peptide Manager Pro; we earn a small commission on referred orders at no additional cost to the buyer.

Is Semax safe for human or animal use?

Semax is sold for in vitro and laboratory research only. It is not intended for human or veterinary administration, and no safety determination for such use has been established by the U.S. Food and Drug Administration or any equivalent regulatory body.